



I. AMENDMENT

IN THE SPECIFICATION:

Please replace the paragraph beginning at page 1, line 3, with the following rewritten paragraph:

-- This application is a continuation of Application No. 08/523,894, filed September 6, 1995, and issued as U.S. Pat. No. 6,136,310, which is a continuation-in-part of Application No. 08/476,237, filed June 7, 1995, and issued as U.S. Pat. No. 5,756,096, which is a continuation-in-part of Application No. 08/379,072, filed ~~April 17~~ January 25, 1995, and issued as U.S. Pat. No. 5,658,570, which is a continuation of Application No. 07/912,292, filed July 10, 1992 (abandoned), which is a continuation-in-part of Application No. 07/856,281, filed March. 23, 1992 (abandoned), and a continuation-in-part of Application No. 07/735,064, filed July 25, 1991 (abandoned). --

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 37-40 and 42-48 are amended, and new claims 49-54 are added.

1-36. (Canceled).

37. (Currently amended) A method of treating a patient having a disease, condition or disorder characterized by an increased number of CD4 positive lymphocytes comprising administering a therapeutically effective amount of a chimeric anti-CD4 antibody that comprises ~~Old World Monkey variable~~ heavy and light chain variable regions of an Old World Monkey antibody and human antibody constant regions, wherein said chimeric antibody inhibits CD4-positive dependent T cell responses.

38. (Currently amended) The method of claim 37 wherein said disease, ~~or condition or disorder~~ is selected from the group consisting of leukemia, lymphoma, asthma, HIV infection, and transplant rejection, and ~~or graft-vs-host~~ graft-versus-host disease.